K. Lockman

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Khalida A Lockman, K. Ann Lockman, K. A. Lockman, K Lockman, K A Lockman, Khalida Ann Lockman, Khalida A. Lockman
Publication record
46 papers · 469 citations · H-index 9

PAPERS

Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof‐Of‐Concept Study
20252 citationsauthor #5
Scottish Society of Physicians 65th Annual Meeting
20240 citationsauthor #32
P34 Gentamicin labels: improving the timing of gentamicin levels and reducing delay in dose administrations
20230 citationsauthor #4
How does discharge against medical advice affect risk of mortality and unplanned readmission? A retrospective cohort study set in a large UK medical admissions unit
202311 citationsauthor #5
Unbiased clustering of exhaled breath profiles in metabolic dysfunction-associated fatty liver disease identifies a patient phenotype at higher risk of disease progression
20220 citationsauthor #3
Improving care for patients in the outlying wards: Lessons from patients' care experience.
20222 citationsauthor #7
O24 Unbiased clustering of breath signature in NAFLD identifies disease progression high-risk patient phenotype- 5 year study
20220 citationsauthor #4
The Effect of Eicosapentaenoic Acid on Hepatic Metabolism and Intracellular Lipid Droplet Dynamics in An in Vitro Model of Hepatic Steatosis
20220 citationsauthor #7
Volatomic analysis identifies compounds that can stratify non-alcoholic fatty liver disease
202043 citationsauthor #2
Long-Term Outcomes of Patients Investigated for Suspected Upper Extremities Deep Venous Thrombosis Irrespective of Imaging Results
20201 citationsauthor #8
Electronic-nose breath print distinguishes non-alcoholic fatty liver disease from healthy lean control: A pilot study
20180 citationsauthor #3
Effective acute care handover to GP: optimising the structure to improve discharge documentation.
20182 citationsauthor #1
A study of breath metabolome in Non-alcoholic fatty liver disease
20181 citationsauthor #2
Carvedilol is associated with improved survival in patients with decompensated cirrhosis
20171 citationsauthor #2
Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites.
201797 citationsauthor #2
Reply to: "Carvedilol and survival in cirrhosis with ascites: A cognitive bias?"
20170 citationsauthor #2
Carvedilol is associated with improved survival in patients with liver cirrhosis and ascites
20170 citationsauthor #2
Erratum to: Fibrinogen production is enhanced in an in-vitro model of non-alcoholic fatty liver disease: an isolated risk factor for cardiovascular events?
20160 citationsauthor #8
Risk of death following admission to a UK hospital with diabetic ketoacidosis
2016149 citationsauthor #4
Editorial: screening for NAFLD – a promising strategy to mitigate future burden of liver disease
20161 citationsauthor #2
The use of hemostatic spray as an adjunct to conventional hemostatic measures in high-risk nonvariceal upper GI bleeding (with video).
201637 citationsauthor #2
Excess long-term mortality in outpatient deep venous thrombosis patients managed in an ambulatory care setting
20161 citationsauthor #5
Proteomic profiling of cellular steatosis with concomitant oxidative stress in vitro
201617 citationsauthor #1
Fibrinogen production is enhanced in an in-vitro model of non-alcoholic fatty liver disease: an isolated risk factor for cardiovascular events?
201517 citationsauthor #8
Editorial: alcohol and obesity – the double peril
20150 citationsauthor #1
Fibrinogen production is enhanced in an in-vitro model of non-alcoholic fatty liver disease: an isolated risk factor for cardiovascular events?
20150 citationsauthor #8
HEPSYS-III PROTEOMICS PROFILING OF IN VITRO CELLULAR STEATOSIS MODEL: THE ROLE OF OXIDATIVE STRESS AND MITOCHONDRIAL DYSFUNCTION IN THE PROGRESSION OF NAFLD
20130 citationsauthor #1
HEPSYS-II METABOLOMICS PROFILING OF AN IN VITRO MODEL OF CELLULAR STEATOSIS: DICARBOXYLIC ACIDS AND EICOSANOIDS AS MARKERS OF ENHANCED LIPID PEROXIDATION AND FATTY ACID OXIDATION DYSREGULATION
20130 citationsauthor #1
HEPSYS-I MICROARRAY EXPRESSION PROFILING OF AN IN VITRO 'NUTRIENT EXCESS' MODEL OF NAFLD IN HUMAN HEPATOCYTES
20130 citationsauthor #5
OC-007 Oxidative Stress Rather than Triglyceride Accumulation Perturbs Glutathione Metabolism in an in Vitro Model of Cellular Steatosis
20133 citationsauthor #1
The relationship between oxidative stress, triglyceride accumulation and mitochondrial function in in vitro model of hepatocellular steatosis
20130 citationsauthor #1
HEPSYS-IV PROTEOMICS PROFILING OF HUMAN ALF PLASMA REVEALS CLINICALLY-RELEVANT PROTEIN EXPRESSION PATTERNS
20130 citationsauthor #6
Oxidative stress rather than triglyceride accumulation is a determinant of mitochondrial dysfunction in in vitro models of hepatic cellular steatosis
201243 citationsauthor #1
1269 OLEATE UPREGULATES LECTIN GALACTOSIDE-BINDING SOLUBLE, 2 (LGALS2) IN MODEL OF CELLULAR STEATOSIS
20110 citationsauthor #1
Oleate upregulates lectin galactoside-binding soluble 2 (LGALS2) in in vitro model of cellular steatosis
20110 citationsauthor #1
Comparison of the effects of long-term pioglitazone and rosiglitazone therapy on liver enzymes in type 2 diabetes
20112 citationsauthor #2
Interrelationships between hepatic fat and insulin resistance in non-alcoholic fatty liver disease.
201035 citationsauthor #1
P53 The contrasting effect of octanoate and oleate on phosphatase and tensin homologue expression in in vitro model of steatosis using HepG2/C3A cells
20100 citationsauthor #1
THE EFFECT OF FREE FATTY ACID AND REACTIVE OXYGEN SPECIES ON CIDEB EXPRESSION IN IN VITRO MODEL OF STEATOSIS
20102 citationsauthor #1
PWE-002 Cell growth is impaired in a cellular model of non-alcoholic fatty liver disease, but is unaffected by simple steatosis
20101 citationsauthor #2
N-acetylcysteine reduces gluconeogenesis without altering hepatic lipid accumulation or mitochondrial superoxide production in an in vitro model of NAFLD
20090 citationsauthor #1
IN VITRO HEPATOCYTE REACTIVE OXYGEN SPECIES PRODUCTION IS NOT RELATED TO THE DEGREE OF FAT ACCUMULATION
20080 citationsauthor #1
943 DO ABNORMAL LIVER FUNCTION TESTS IMPROVE WITH INSULIN THERAPY IN TYPE 2 DIABETES
20080 citationsauthor #1
The relationship between reactive oxygen species, insulin resistance and nonalcoholic fatty liver disease. A study using in vitro model
20080 citationsauthor #1
985 THE IMPACT OF LONG-TERM PIOGLITAZONE THERAPY ON ABNORMAL LIVER ENZYMES IN TYPE 2 DIABETES
20080 citationsauthor #2

TIMELINE

2008 0 citations

2009 0 citations

2010 38 citations

2011 2 citations

2012 43 citations

2013 3 citations

2015 17 citations

2016 205 citations

2017 98 citations

2018 3 citations

2020 44 citations

2022 2 citations

2023 11 citations

2024 0 citations

2025 2 citations

K. Lockman

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT